Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Leukemia, Myelomonocytic, Juvenile 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Ifosfamide 5Doxorubicin 4Specimen Handling 3Methotrexate 3Etoposide 3Cisplatin 3Sorafenib 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2sodium thiosulfate 1sargramostim 1pepinemab 1peginterferon alfa-2b 1mifamurtide 1merphos 1lorukafusp alfa 1irinotecan sucrosofate 1imetelstat 1etoposide phosphate 1Zoledronic Acid 1X-Rays 1Thrombopoietin 1Thoracotomy 1Thoracostomy 1Thoracoscopy 1Surgical Procedures, Operative 1Reverse Transcriptase Polymerase Chain Reaction 1Restraint, Physical 1Razoxane 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Osteosarcoma × GRN163L peptide × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡